Prothena Corp plc 2026年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March31, 2026 Commission file number: 001-35676______________________________________ PROTHENA CORPORATION PUBLIC LIMITED COMPANY(Exact name of registrant as specified in its charter) ______________________________________ Ireland(State or other jurisdiction ofincorporation or organization) 98-1111119(I.R.S. EmployerIdentification Number) Registrant’s telephone number, including area code:011-353-1-236-2500______________________________________ Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and(2)has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reportingcompany” and “emerging growth company” in Rule12b-2 of the Exchange Act. Accelerated filer☒Smallerreportingcompany☐Emerging growth company☐ Large accelerated filer☐Non-accelerated filer☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition periodfor complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act).Yes☐No☒ The number of ordinary shares outstanding was 52,353,237 as of April30, 2026. PROTHENA CORPORATION PLCForm 10-Q – QUARTERLY REPORTFor the Quarter Ended March31, 2026 TABLE OF CONTENTS Item1. Financial Statements (unaudited)1Condensed Consolidated Balance Sheets as of March31, 2026 and December31, 20251Condensed Consolidated Statements of Operations for the three months ended March 31, 2026 and 20252Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 20253Condensed Consolidated Statements of Shareholders' Equity for the three months ended March 31, 2026 and 20255Notes to Condensed Consolidated Financial Statements6Item2. Management’s Discussion and Analysis of Financial Condition and Results of Operations20Item3. Quantitative and Qualitative Disclosures About Market Risk32Item4. Controls and Procedures33 PART II. OTHER INFORMATIONItem1. Legal ProceedingsItem1A. Risk FactorsItem2. Unregistered Sales of Equity Securities and Use of ProceedsItem3. Defaults Upon Senior SecuritiesItem4. Mine Safety DisclosuresItem5. Other InformationItem6. Exhibits SIGNATURESEXHIBIT INDEX Note Regarding Forward-Looking Statements In addition to historical information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning ofSection21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may include words such as “aim,”“anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective”“plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictionsof or indicate future events and future trends, or the negative of these terms or other comparable terminology. In addition, any statementsthat refer to expectations, projections, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements, which reflect our beliefs, assumptions, expectations, estimates, forecasts, and projections aboutour business and the industry in which we operated as of the date hereof, are estimates based on our best judgment. These statements relateto, among other things, our goal to continue building a biology-directed discovery engine targeting protein dysregulation; the treatmentpotential, designs, proposed mechanisms of action, and potential administration of our drug candidates; potential indications and attributesof epitopes and antibodies we have identified in our programs; plans for ongoing and future clinical trials of our drug candidates; ourpotential to advance, initiate, and complete investigational new drug (“IND”) enabling studies for our discovery and preclinical programs;the expected timing of reporting data from clinical trials of our drug candidates; our c